Glucovance® (glibenclamide and metformin) is a fixed-dose combination therapy for type 2 diabetes containing two anti-hyperglycemic drugs. Single treatments have limitations over time in achieving normal glucose levels because of the progressive nature of type 2 diabetes. The combination of metformin, a member of the biguanide class of molecules which decrease glucose production by the liver, with glibenclamide, a sulphonylurea which targets the pancreas and helps stimulate insulin release, is designed to help physicians in achieving target goals of near-normal blood glucose levels.

Glucovance® is part of the Glucophage family of oral antidiabetics marketed by Merck Serono, a world leader in oral diabetes medications. More than six million patients in over 100 countries around the globe currently benefit from various products of the Glucophage® family.